对比剂脑病研究进展  

Research advancements of contrast-induced encephalopathy

作　　者：邵东传 吴钧[1] 高云[1] 刘俊[1] 马钢[1] 苏平[1] 普快荣 岑键昌[1] SHAO Dongchuan;WU Jun;GAO Yun;LIU Jun;MA Gang;SU Ping;PU Kuairong;CEN Jianchang(Department of Neurosurgery, the First People's Hospital of Kunming City, Kunming 650034, China)

机构地区：[1]昆明市第一人民医院神经外科,云南昆明650034

出　　处：《中国介入影像与治疗学》2021年第8期497-500,共4页Chinese Journal of Interventional Imaging and Therapy

基　　金：云南省医疗卫生单位资助项目(2017NS086)。

摘　　要：随着医学影像学技术快速发展,对比剂应用日渐广泛,相关不良反应随之增加。对比剂脑病(CIE)是应用对比剂后出现的短暂性、可逆性神经功能障碍性疾病,多预后良好,但少数患者可出现严重神经功能障碍甚至死亡。本文对CIE临床特点、发病机制、高危因素及治疗措施等研究进展进行综述。With the rapid development of medical imaging technologies,contrast agents have been widely used,resulting accordingly increase of relative adverse reactions.Contrast-induced encephalopathy(CIE)is a rare adverse reaction,characterized by transient,reversible neurological impairment.Most CIE patients have good prognosis,but severe neurological dysfunction or even death occur in a few patients.The research advancements of clinical characteristics,pathogenesis,high-risk factors and treatment measures of CIE were reviewed in this article.

关 键 词：脑疾病 造影剂 碘 影像增强 

分 类 号：R747.9[医药卫生—神经病学与精神病学] R445[医药卫生—临床医学]